Der Humanized Monoklonal Anti-CLDN18.2 (Zolbetuximab Biosimilar) Antikörper wurde für FACS und in vivo validiert. Er ist geeignet, CLDN18.2 (Zolbetuximab Biosimilar) in Proben von Human zu detektieren.
Produktnummer ABIN7795131
Kurzübersicht für Rekombinanter CLDN18.2 (Zolbetuximab Biosimilar) Antikörper (ABIN7795131)
Target
CLDN18.2 (Zolbetuximab Biosimilar)
Antikörpertyp
Recombinant Antibody
Reaktivität
Human
Wirt
Humanized
Klonalität
Monoklonal
Konjugat
Dieser CLDN18.2 (Zolbetuximab Biosimilar) Antikörper ist unkonjugiert
What is zolbetuximab biosimilar research grade? Zolbetuximab is a humanized monoclonal antibody directed against the human protein Claudin 18.2 (the isoform 2 of Claudin), and potentially used for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. Zolbetuximab is an Fc-engineered, humanized, monoclonal antibody (IgG1κ isotype). Zolbetuximab biosimilar uses the same protein sequences as the potential therapeutic antibody zolbetuximab . Claudin-18 in humans is a protein encoded by the CLDN18 gene. The CLDN18 protein belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. Isoform 2 (Claudin 18.2) is abundant in gastric tumors.